Molecular diagnostics & therapeutics

The AML Hub are pleased to be covering the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting. Here, we review what was...

Editorial theme | The value of FLT3 targeting in AML

FMS-like tyrosine kinase 3 (FLT3) is a transmembrane protein expressed by hematopoietic stem and progenitor cells and is involved in the early...

Treating older patients with AML in 2020: What is new and promising?

Interview with Courtney DiNardo, MD Anderson Cancer Center, at the 25th Congress of the EHA about the treatment of elderly patients...

EHA 2019 round up – FLT3 mutations in AML

Last year, at the European Hematology Association (EHA) meeting, a lot of attention was focused on the FMS-like tyrosine kinase-3 (FLT3) mutations in acute...

Can CD47 antibody therapy be safely used for AML and MDS?

Podcast discussion between David Sallman, Moffitt Cancer Center, and Naval Daver, MD Anderson Cancer Center, held during the 25th Congress of...

The role of the Nlrp3 inflammasome in hematological pathologies

The Nlrp3 inflammasome has recently gained a lot of attention due to its reported involvement in various hematological pathologies,...

Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak...

AML World Awareness Day 2020 | The value of measurable residual disease in acute myeloid leukemia

Although up to 80% of patients with AML achieve morphologic complete remission (mCR) following...

Magrolimab plus azacytidine in patients with myelodysplastic syndromes and acute myeloid leukemia

During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, David Sallman from the...

Ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies

Curtis Lachowiez from The University of Texas, MD Anderson Cancer Center, Houston, TX, US, reported an interim analysis at...

Do you see improved outcomes when adding magrolimab to azacitidine in MDS and AML treatment?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was delighted to speak...

How does the type of prior treatment affect the risk of therapy-related myeloid neoplasms?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, Alexander Maurer from the AML Hub...